Brief: Compugen On Track To Present New Com701/Nivolumab Mss-Crc Data In Q4 2022
22/09/2022 12:13
Sept 22 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN LTD - ON TRACK TO PRESENT NEW COM701/NIVOLUMAB
MSS-CRC
DATA IN Q4 2022
Source text for Eikon: ID:nPn77w2yra
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025